50% off Premium Yearly
Projected 19% earnings growth in 2026, yet trades at under 12x PE 2026. Has a robust drug pipeline.
Stock price when the opinion was issued
As of Jun 12, 2026. Market Open.
The momentum has broken badly and has a high PE. But he entered this on a rebound that has momentum. Despite an upgrade today, he doesn't see a green light ahead.
Build your watch list
Sign in to track investmentsyou care about
CNBC
RN Croft Financial Group
5i Research
Stockchase Premium
Private Wealth Management, ScotiaMcleod
Projected 19% earnings growth in 2026, yet trades at under 12x PE 2026. Has a robust drug pipeline.